Damora Therapeutics, Inc. (DMRA)
21.49
-0.52
(-2.36%)
USD |
NASDAQ |
Oct 30, 16:00
21.48
0.00 (0.00%)
After-Hours: 20:00
Damora Therapeutics Net Income (Quarterly) : -31.17M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -31.17M |
| March 31, 2026 | -27.78M |
| December 31, 2025 | -200.74M |
| September 30, 2025 | -3.133M |
| June 30, 2025 | -3.437M |
| March 31, 2025 | -2.533M |
| December 31, 2024 | -6.741M |
| September 30, 2024 | -3.883M |
| June 30, 2024 | -5.338M |
| March 31, 2024 | -5.477M |
| December 31, 2023 | -6.475M |
| September 30, 2023 | -8.136M |
| June 30, 2023 | -10.74M |
| Date | Value |
|---|---|
| March 31, 2023 | -12.99M |
| December 31, 2022 | -14.07M |
| September 30, 2022 | -13.73M |
| June 30, 2022 | -16.89M |
| March 31, 2022 | -16.94M |
| December 31, 2021 | -13.41M |
| September 30, 2021 | -12.70M |
| June 30, 2021 | -12.30M |
| March 31, 2021 | -13.34M |
| December 31, 2020 | -11.58M |
| September 30, 2020 | -11.65M |
| March 31, 2020 | -5.674M |
| September 30, 2019 | -4.105M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 31.17M |
| EPS Diluted (Quarterly) | -0.5099 |
| Enterprise Value | 916.55M |
| Earnings Yield | -580.7% |
| Normalized Earnings Yield | -238.11 |